Glybera

Active Substance: alipogene tiparvovec 
Common Name: alipogene tiparvovec 
ATC Code: C10 AX10
Marketing Authorisation Holder: uniQure biopharma B.V.  
Active Substance: alipogene tiparvovec 
Status: Withdrawn
Authorisation Date: 2012-10-25
Therapeutic Area: Hyperlipoproteinemia Type I
Pharmacotherapeutic Group: Lipid modifying agents

Therapeutic Indication

Glybera is indicated for adult patients diagnosed with familial lipoprotein lipase deficiency (LPLD) and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. The diagnosis of LPLD has to be confirmed by genetic testing. The indication is restricted to patients with detectable levels of LPL protein.

The marketing authorization for Glybera has expired following the marketing-authorization holder’s decision not to apply for a renewal.

GLIBERA

Glybera

INN:

alipogene tiparvovec

MANUFACTURER:

uniQurо (Netherlands)

• NF

  NOSOLOGICAL FORM:

  orphan, endocrinological
• 
  

• 142717, MOSCOW REGION, LENINSKY DISTRICT, POS. FORK, QUARTER 1, POSSESSION 09, OFFICE 5 

  phone: +7 (913) 445-12-02, +7 (961) 896-69-53
  e-mail: Tsypysheva.av@farmamondovostok.ru 
• https://farmamondovostok.ru/en/contacts/